 Muscular Dystrophy, Duchenne
"Muscular Dystrophy, Duchenne" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Descriptor ID |
D020388
|
| MeSH Number(s) |
C05.651.534.500.300 C10.668.491.175.500.300 C16.320.322.562 C16.320.577.300
|
| Concept/Terms |
Muscular Dystrophy, Duchenne- Muscular Dystrophy, Duchenne
- Cardiomyopathy, Dilated, X-Linked
- Childhood Muscular Dystrophy, Pseudohypertrophic
- Childhood Pseudohypertrophic Muscular Dystrophy
- Duchenne Muscular Dystrophy
- Duchenne-Type Progressive Muscular Dystrophy
- Duchenne Type Progressive Muscular Dystrophy
- Muscular Dystrophy, Childhood, Pseudohypertrophic
- Muscular Dystrophy, Duchenne Type
- Muscular Dystrophy, Pseudohypertrophic
- Pseudohypertrophic Muscular Dystrophy
- Muscular Dystrophy, Pseudohypertrophic Progressive, Duchenne Type
- Muscular Dystrophy, Pseudohypertrophic, Childhood
- Progressive Muscular Dystrophy, Duchenne Type
- Pseudohypertrophic Childhood Muscular Dystrophy
- Pseudohypertrophic Muscular Dystrophy, Childhood
- Cardiomyopathy, Dilated, 3B
Duchenne and Becker Muscular Dystrophy- Duchenne and Becker Muscular Dystrophy
- Muscular Dystrophy, Duchenne and Becker Types
- Duchenne-Becker Muscular Dystrophy
- Duchenne Becker Muscular Dystrophy
- Muscular Dystrophy, Duchenne-Becker
Becker Muscular Dystrophy- Becker Muscular Dystrophy
- Muscular Dystrophy, Pseudohypertrophic Progressive, Becker Type
- Muscular Dystrophy, Becker
- Muscular Dystrophy, Becker Type
- Becker's Muscular Dystrophy
- Muscular Dystrophy, Becker's
- Muscular Dystrophy Pseudohypertrophic Progressive, Becker Type
|
Below are MeSH descriptors whose meaning is more general than "Muscular Dystrophy, Duchenne".
- Diseases [C]
- Musculoskeletal Diseases [C05]
- Muscular Diseases [C05.651]
- Muscular Disorders, Atrophic [C05.651.534]
- Muscular Dystrophies [C05.651.534.500]
- Muscular Dystrophy, Duchenne [C05.651.534.500.300]
- Nervous System Diseases [C10]
- Neuromuscular Diseases [C10.668]
- Muscular Diseases [C10.668.491]
- Muscular Disorders, Atrophic [C10.668.491.175]
- Muscular Dystrophies [C10.668.491.175.500]
- Muscular Dystrophy, Duchenne [C10.668.491.175.500.300]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Genetic Diseases, X-Linked [C16.320.322]
- Muscular Dystrophy, Duchenne [C16.320.322.562]
- Muscular Dystrophies [C16.320.577]
- Muscular Dystrophy, Duchenne [C16.320.577.300]
Below are MeSH descriptors whose meaning is more specific than "Muscular Dystrophy, Duchenne".
This graph shows the total number of publications written about "Muscular Dystrophy, Duchenne" by people in this website by year, and whether "Muscular Dystrophy, Duchenne" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 2 | 0 | 2 | | 2011 | 3 | 0 | 3 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 5 | 0 | 5 | | 2015 | 6 | 0 | 6 | | 2016 | 2 | 0 | 2 | | 2017 | 4 | 1 | 5 | | 2018 | 11 | 0 | 11 | | 2019 | 4 | 0 | 4 | | 2020 | 4 | 1 | 5 | | 2021 | 7 | 0 | 7 | | 2022 | 7 | 0 | 7 | | 2023 | 4 | 0 | 4 | | 2024 | 3 | 2 | 5 | | 2025 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Muscular Dystrophy, Duchenne" by people in Profiles.
-
Du X, Nakanishi H, Yamada T, Sin Y, Minegishi K, Motohashi N, Aoki Y, Itaka K. Polyplex Nanomicelle-Mediated Pgc-1a4 mRNA Delivery Via Hydrodynamic Limb Vein Injection Enhances Damage Resistance in Duchenne Muscular Dystrophy Mice. Adv Sci (Weinh). 2025 Apr; 12(16):e2409065.
-
Esteso P, Auerbach SR, Bansal N, Harris R, Soslow JH, Birnbaum BF, Conway J, Cripe LH, Nandi D, Hayes E, Gambetta KE, Hall EK, Hsu DT, Kaufman BD, Rosenthal D, Kirmani S, Ploutz MS, Lal AK, Peng DM, Villa CR, Shugh S, Wittlieb-Weber CA, Shih R. Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee. Cardiol Young. 2025 Apr; 35(4):770-775.
-
Ward LM, Weber DR, Wong SC, Apkon S, Clemens PR, Cripe LH, McMillan HJ, Mercuri E, Nasomyont N, Phung K, Renthal NE, Rutter MM, Tian C, Wood CL, Zeitler PS, Buccella F, Kinnett K, Furlong P. A Parent Project Muscular Dystrophy-sponsored International Workshop Report on Endocrine and Bone Issues in Patients with Duchenne Muscular Dystrophy: An Ever-changing Landscape. J Neuromuscul Dis. 2025 Jan-Feb; 12(1):22143602241303370.
-
Upadhyay V, Ray S, Panja S, Saviola AJ, Maluf NK, Mallela KMG. Biophysical characterization of the dystrophin C-terminal domain: Dystrophin interacts differentially with dystrobrevin isoforms. J Biol Chem. 2024 Dec; 300(12):108002.
-
Crossnohere NL, Campoamor NB, Camino E, Dresnick E, Martschenko DO, Rodrigues V, Apkon S, Hazlett A, Mittur D, Rodriguez PE, Bridges JFP, Armstrong N. Barriers to diverse clinical trial participation in Duchenne muscular dystrophy: Engaging Hispanic/Latina caregivers and health professionals. Orphanet J Rare Dis. 2024 May 21; 19(1):207.
-
Pickart AM, Martin AS, Gross BN, Dellefave-Castillo LM, McCallen LM, Nagaraj CB, Rippert AL, Schultz CP, Ulm EA, Armstrong N. Genetic counseling for the dystrophinopathies-Practice resource of the National Society of Genetic Counselors. J Genet Couns. 2025 Feb; 34(1):e1892.
-
Dang UJ, Damsker JM, Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, Mah JK, Deconinck N, Goemans NM, Haberlov? J, Straub V, Mengle-Gaw L, Schwartz BD, Harper A, Shieh PB, De Waele L, Castro D, Yang ML, Ryan MM, McDonald CM, Tulinius M, Webster RI, Mcmillan HJ, Kuntz N, Rao VK, Baranello G, Spinty S, Childs AM, Sbrocchi AM, Selby KA, Monduy M, Nevo Y, Vilchez JJ, Nascimento-Osorio A, Niks EH, De Groot IJM, Katsalouli M, Van Den Anker JN, Ward LM, Leinonen M, D'Alessandro AL, Hoffman EP. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Neurology. 2024 Mar 12; 102(5):e208112.
-
Armstrong N, Apkon S, Berggren KN, Braun C, Ciafaloni E, Connolly A, Kennedy A, Kuntz N, Mathews K, McGuire M, Parad R, Scavina M, Scharf RJ, Waldrop M. The Early Care (0-3 Years) In Duchenne Muscular Dystrophy Meeting Report. J Neuromuscul Dis. 2024; 11(2):525-533.
-
Russell AJ, DuVall M, Barthel B, Qian Y, Peter AK, Newell-Stamper BL, Hunt K, Lehman S, Madden M, Schlachter S, Robertson B, Van Deusen A, Rodriguez HM, Vera C, Su Y, Claflin DR, Brooks SV, Nghiem P, Rutledge A, Juehne TI, Yu J, Barton ER, Luo YE, Patsalos A, Nagy L, Sweeney HL, Leinwand LA, Koch K. Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy. J Clin Invest. 2023 05 15; 133(10).
-
Gorokhova S, Schessl J, Zou Y, Yang ML, Heydemann PT, Sufit RL, Meilleur K, Donkervoort S, Medne L, Finkel RS, B?nnemann CG. Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin. Med. 2023 04 14; 4(4):245-251.e3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|